A Double-Blind Placebo Controlled Trial of Ginkgo biloba Added to Risperidone in Patients with Autistic Disorders
| العنوان: | A Double-Blind Placebo Controlled Trial of Ginkgo biloba Added to Risperidone in Patients with Autistic Disorders |
|---|---|
| المؤلفون: | Mina Tabrizi, Farzin Rezaei, Ahmad Ghanizadeh, Elmira Hasanzadeh, Shahin Akhondzadeh, Mohammad Reza Mohammadi, Shamsali Rezazadeh |
| المصدر: | Child Psychiatry & Human Development. 43:674-682 |
| بيانات النشر: | Springer Science and Business Media LLC, 2012. |
| سنة النشر: | 2012 |
| مصطلحات موضوعية: | Male, medicine.medical_specialty, Side effect, Placebo-controlled study, Administration, Oral, Child Behavior, Iran, Placebo, law.invention, Double-Blind Method, Randomized controlled trial, law, Internal medicine, Developmental and Educational Psychology, medicine, Humans, Child, Psychiatry, Psychiatric Status Rating Scales, Risperidone, biology, Plant Extracts, Ginkgo biloba, medicine.disease, biology.organism_classification, Diagnostic and Statistical Manual of Mental Disorders, Clinical trial, Psychiatry and Mental health, Treatment Outcome, Child Development Disorders, Pervasive, Child, Preschool, Pediatrics, Perinatology and Child Health, Autism, Drug Therapy, Combination, Female, Psychology, Antipsychotic Agents, Phytotherapy, medicine.drug |
| الوصف: | Ginkgo biloba has been reported to affect the neurotransmitter system and to have antioxidant properties that could impact the pathogenesis of Autism Spectrum Disorder. Based on these studies, we decided to assess the effectiveness of Ginkgo biloba extract (Ginko T.D., Tolidaru, Iran) as an adjunctive agent to risperidone in the treatment of autism. Forty-seven outpatients with a DSM-IV-TR diagnosis of autism ages between 4 and 12 years were assigned to this double blinded clinical trial and were randomly divided into two groups. One group received risperidone plus Ginko T.D and the other received risperidone plus placebo. The dose of risperidone was 1-3 mg/day and the dose of Ginko T.D. was 80 mg/day for patients under 30 kg and 120 mg/day for patients above 30 kg. Patients were assessed using Aberrant Behavior Checklist-Community (ABC-C) rating scale and the side effect check list every 2 weeks until the endpoint. None of the 5 subscales of ABC-C rating scale showed significant differences between the two groups. Incidents of side effects were not significantly different between the two groups. Adding Ginkgo biloba to risperidone did not affect the treatment outcome of ADs. Nevertheless, further observations are needed to confirm this result. |
| تدمد: | 1573-3327 0009-398X |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e719228d72085e0063c57ec8f165433e https://doi.org/10.1007/s10578-012-0292-3 |
| حقوق: | CLOSED |
| رقم الأكسشن: | edsair.doi.dedup.....e719228d72085e0063c57ec8f165433e |
| قاعدة البيانات: | OpenAIRE |
Find this article in full text from Springer Verlag. | تدمد: | 15733327 0009398X |
|---|